AMLX: Amylyx Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 233.75
Enterprise Value ($M) -0.65
Book Value ($M) 196.20
Book Value / Share 2.86
Price / Book 1.19
NCAV ($M) 190.75
NCAV / Share 2.78
Price / NCAV 1.23

Profitability (mra)
Return on Invested Capital (ROIC) -1.31
Return on Assets (ROA) -0.50
Return on Equity (ROE) -0.60

Liquidity (mrq)
Quick Ratio 4.72
Current Ratio 4.72

Balance Sheet (mrq) ($M)
Current Assets 245.26
Assets 250.71
Liabilities 54.51
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
01-14 13G Point72 Asset Management, L.P.
11-12 13G/A Vanguard Group Inc 4.53 0.00
10-25 13G Perceptive Advisors Llc 6.50 138.55
08-26 13G TCG Crossover GP II, LLC 6.80
07-08 13G/A BlackRock, Inc. 3.90 -33.30
03-11 13G Panacea Innovation Ltd 6.20
02-14 13G/A Viking Global Investors Lp 4.40 -36.08

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 94,395 895,519 10.54
2025-02-03 101,242 775,820 13.05
2025-01-31 78,985 1,275,603 6.19
2025-01-30 45,619 369,829 12.34

(click for more detail)

Similar Companies
ALNY – Alnylam Pharmaceuticals, Inc. ALXO – ALX Oncology Holdings Inc.
AMGN – Amgen Inc. AMPH – Amphastar Pharmaceuticals, Inc.
AMRX – Amneal Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io